2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Molecular Testing, Clinical Procedures, Treatment Considerations, Combination Therapy, Supportive Care, Therapy Sequence, Biological Therapies, Transplantation, Women’s Health, Adverse Events, Artificial Intelligence (AI), Machine Learning, Biological Processes, CHIP, Genomics, Molecular Biology, Clinical Practice (Health Services and Quality), Clinical Guidelines, Patient Safety, Quality Improvement, Quality of Care, Systems-Based Hematology, Diseases, Bone Marrow Failure Syndromes, Aplastic Anemia, Genetic Disorders, Immunology, Autoimmune Disorders, Autoimmune Hemolytic Anemia, GVHD, Infectious Diseases, Viral, Bacterial, Fungal, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, ALL, CLL, LGL, Hodgkin Lymphoma, Non-Hodgkin Lymphoma, B Cell Lymphoma, T Cell Lymphoma, Research, AML, Translational Research, MDS, MPN, CML, Clinical Research, Epidemiology, Health Outcomes Research, Real-World Evidence, Survivorship, Study Population, Human, Adult, Elderly, Pediatric
PAPER

2494 Co-mutation patterns define post-transplant risk in RUNX1-mutated myeloid neoplasms: A multicenter trophy study

Yiqiu Zheng, Lixia Zhu2, Jimin Shi3, Yi Luo4, Yeqian Zhao5, Weiyan Zheng6, Jie Sun, PhD7, Xiu-Jin Ye8, Jian Yu9, Lizhen Liu10, Yang Cao, MD11, Xiaoyu Lai12, Xiaoxia Hu, MD13, Wei Shi14, He Huang, MD, PhD15, Yanmin Zhao, MD16
1 Bone Marrow Transplantation Center, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China
2 Bone Marrow Transplantation Center, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China
3 Bone Marrow Transplantation Center, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China
4 Bone Marrow Transplantation Center, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China
5 Bone Marrow Transplantation Center, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China
6 Bone Marrow Transplantation Center, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China
7 Bone Marrow Transplantation Center, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China
8 Bone Marrow Transplantation Center, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China
9 Bone Marrow Transplantation Center, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China
10 Bone Marrow Transplantation Center, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China
11 Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
12 Bone Marrow Transplantation Center, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China
13 State Key Laboratory of Medical Genomics, Shanghai Institute of Hematology, National Research Center for Translational Medicine, Shanghai Rui Jin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
14 Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
15 Bone Marrow Transplantation Center, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China
16 Bone Marrow Transplantation Center, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China

Background

RUNX1-mutated myeloid neoplasms are clinically and molecularly heterogeneous. Allogeneic hematopoietic stem cell transplantation (allo-HCT) is potentially curative, but post-transplant relapse remians common. Whether intrinsic RUNX1 features or co-mutation patterns identify patients at particularly high risk after allo-HCT remains unclear. We evaluated the association of allo-HCT with survival and investigated clinical and molecular determinants of post-transplant outcomes.

Methods

We retrospectively included consecutive patients with newly diagnosed RUNX1-mutated de novo acute myeloid leukemia (AML), secondary AML, or myelodysplastic syndromes treated at TROPHY centers between 2017 and 2025. Mutations were assessed by next-generation sequencing at diagnosis. In the overall cohort, overall survival (OS) was measured from diagnosis, and allo-HCT was modeled as a time-dependent exposure in multivariable Cox regression. Among transplant recipients, OS and relapse-free survival (RFS) were measured from allo-HCT. Cumulative incidences of relapse (CIR) and nonrelapse mortality (NRM) were analyzed using competing-risk methods.

Results

Among 3600 patients with myeloid neoplasms screened, 367 had RUNX1 mutation, including 266 with de novo AML, 62 with MDS, and 39 with sAML. The median age was 54 years (interquartile range [IQR], 47–67). The median RUNX1 variant allele frequency (VAF) was 37% (IQR, 18%–45%); 326 patients (89%) had a single RUNX1 mutation and 41 (11%) had multiple RUNX1 mutations. Overall, 187 patients (51%) underwent allo-HCT.

With a median follow-up of 24.4 months, allo-HCT was independently associated with longer OS when modeled as a time-dependent exposure (adjusted hazard ratio [HR], 0.53; 95% CI, 0.33–0.84; P=0.007). RUNX1 mutation multiplicity, VAF, functional class, and affected protein domain were not associated with OS. In contrast, co-occurring transcription-factor mutations (aHR, 1.59; 95% CI, 1.07–2.36; P=0.020) and RAS/MAPK-pathway mutations (aHR, 1.97; 95% CI, 1.36–2.83; P<0.001) were independently associated with inferior OS.

Among allo-HCT recipients, the associations of pre-transplant remission status with OS and RFS differed according to diagnosis. Among AML patients, a bone marrow blast <5% at transplantation was associated with superior 3-year OS (74.2% vs 49.9%) and RFS (69.7% vs 24.2%) compared with a blast count ≥5%. However, no clear association between pretransplant marrow blast burden and outcomes was observed in patients with MDS. Most intrinsic RUNX1 features, such as RUNX1 mutation multiplicity, VAF and affected protein domain, were not independently prognostic after transplantation, although truncating variants showed a borderline association with inferior RFS (aHR, 2.14; 95% CI 1.00–4.59, P=0.050). Cytogenetic risk and additional myelodysplasia-related gene mutations were not independently prognostic.

Co-occurring transcription-factor mutations were independently associated with inferior post-transplant OS (aHR, 2.36; 95% CI, 1.24–4.50; P=0.008) and RFS (aHR, 2.84; 95% CI, 1.27–6.37; P=0.011). RAS/MAPK-pathway mutations were also associated with inferior post-transplant OS (aHR, 2.21; 95% CI, 1.16–4.23; P=0.016), but not significantly with RFS (aHR, 1.66; 95% CI, 0.73–3.79; P=0.222).

Based on the concordant adverse effects of these mutation categories, we explored an integrated molecular classification. Fifteen (8.0%) had concurrent RAS/MAPK-pathway and transcription-factor mutations. Three-year OS was 23.3%, 81.3%, and 73.5% in double-positive, double-negative, and single-positive patients, respectively. Corresponding RFS rates were 29.0%, 77.9%, and 56.6%, and CIR rates were 62.0%, 20.2%, and 37.7%. NRM did not differ significantly. After adjustment for disease status, measurable residual disease, cytogenetic risk, conditioning intensity, and donor type, double-positive subgroup remained independently associated with inferior RFS (aHR, 7.27; 95% CI, 2.95–17.90; P<0.001) and OS (aHR, 6.19; 95% CI, 2.74–14.00; P<0.001).

Conclusions

Allo-HCT was independently associated with longer OS in RUNX1-mutated myeloid neoplasms. Post-transplant outcomes were more strongly associated with co-mutation background than with intrinsic RUNX1 features. Concurrent transcription-factor and RAS/MAPK-pathway mutations identified an exploratory subgroup with markedly increased risks of relapse and death, warranting independent validation.

Yiqiu Zheng: No relevant conflicts of interest to declare.